CHAPTER 1: INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. KEY PLAYERS
1.5. RESEARCH METHODOLOGY

1.5.1. Secondary research
1.5.2. Primary research
1.5.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of new entrants
3.3.4. Intensity of rivalry
3.3.5. Threat of substitutes

3.4. MARKET SHARE ANALYSIS, 2017
3.5. GOVERNMENT REGULATIONS

3.5.1. U.S. FDA
3.5.2. Europe CE Mark
3.5.3. Ministry of Health, Labour and Welfare (MHLW)

3.6. CLINICAL TRIALS
3.7. MARKET DYNAMICS

3.7.1. Drivers

3.7.1.1. Rise in prevalence of aortic stenosis coupled with increase in geriatric population
3.7.1.2. Increase in adoption rate for transcatheter aortic valve implantation procedure
3.7.1.3. Increase in clinical evidence of safety and efficacy and new device approvals
3.7.1.4. Increase in number of TAVR Centers

3.7.2. Restraints

3.7.2.1. High cost of the device and unfavorable reimbursement policies
3.7.2.2. Stringent regulatory approval process

3.7.3. Opportunities

3.7.3.1. Use of TAVI systems for new indications
3.7.3.2. Rise in healthcare expenditure of developing countries
3.7.3.3. Increase in interest of local to global players in the TAVI market

3.7.4. Impact Analyses

CHAPTER 4: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY PROCEDURE

4.1. OVERVIEW

4.1.1. Key market trends, growth factors, and opportunities
4.1.2. Market size and forecast
4.1.3. Market volume and forecast

4.2. TRANSFEMORAL (TF) IMPLANTATION

4.2.1. Market size and forecast
4.2.2. Market volume and forecast

4.3. TRANSAPICAL (TA) IMPLANTATION

4.3.1. Market size and forecast
4.3.2. Market volume and forecast

4.4. TRANSAORTIC IMPLANTATION

4.4.1. Market size and forecast
4.4.2. Market volume and forecast

CHAPTER 5: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast
5.1.2. Market volume and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.2.3. Market volume and forecast, by country

5.2.3.1. U.S.
5.2.3.2. Canada
5.2.3.3. Mexico

5.2.4. Market size and forecast, by procedure
5.2.5. Market volume and forecast, by procedure

5.3. EUROPE

5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.3.3. Market volume and forecast, by country

5.3.3.1. Germany
5.3.3.2. France
5.3.3.3. Italy
5.3.3.4. Switzerland
5.3.3.5. UK
5.3.3.6. Rest of Europe

5.3.4. Market size and forecast, by procedure
5.3.5. Market volume and forecast, by procedure

5.4. ASIA-PACIFIC

5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
5.4.3. Market volume and forecast, by country

5.4.3.1. Japan
5.4.3.2. China
5.4.3.3. India
5.4.3.4. Rest of Asia-Pacific

5.4.4. Market size and forecast, by procedure
5.4.5. Market volume and forecast, by procedure

5.5. LAMEA

5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast, by country
5.5.3. Market volume and forecast, by country

5.5.3.1. Brazil
5.5.3.2. South Africa
5.5.3.3. Israel
5.5.3.4. Saudi Arabia
5.5.3.5. Rest of LAMEA

5.5.4. Market size and forecast, by procedure
5.5.5. Market volume and forecast, by procedure

CHAPTER 6: COMPANY PROFILES

6.1. ABBOTT LABORATORIES (ST. JUDE MEDICAL, INC.)

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments

6.2. BOSTON SCIENTIFIC CORPORATION (SYMETIS SA)

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments

6.3. BRACCO S.P.A. (HLT, INC.)

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance

6.4. EDWARDS LIFESCIENCES CORPORATION

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments

6.5. JENAVALVE TECHNOLOGY, INC.

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio

6.6. JC MEDICAL, INC.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Product portfolio
6.6.4. Key strategic moves and developments

6.7. MEDTRONIC PLC.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments

6.8. MERIL LIFE SCIENCES PVT. LTD.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio

6.9. NVT AG

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Product portfolio

6.10. VENUS MEDTECH, INC.

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Product portfolio
6.10.4. Key strategic moves and developments